WO1995011227B1 - Novel spin trap nitronyl hindered phenols - Google Patents

Novel spin trap nitronyl hindered phenols

Info

Publication number
WO1995011227B1
WO1995011227B1 PCT/US1994/012107 US9412107W WO9511227B1 WO 1995011227 B1 WO1995011227 B1 WO 1995011227B1 US 9412107 W US9412107 W US 9412107W WO 9511227 B1 WO9511227 B1 WO 9511227B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
tert
nitronyl
butyl
Prior art date
Application number
PCT/US1994/012107
Other languages
French (fr)
Other versions
WO1995011227A1 (en
Filing date
Publication date
Priority claimed from US08/141,241 external-priority patent/US5455272A/en
Application filed filed Critical
Priority to CA002174628A priority Critical patent/CA2174628C/en
Priority to DE69420146T priority patent/DE69420146T2/en
Priority to EP94931977A priority patent/EP0724565B1/en
Priority to AU80869/94A priority patent/AU696451B2/en
Publication of WO1995011227A1 publication Critical patent/WO1995011227A1/en
Publication of WO1995011227B1 publication Critical patent/WO1995011227B1/en

Links

Abstract

The invention is the use of nitronyl substituted hindered phenols as antioxidants in therapeutic applications. In the preferred embodiment the compositions have general formula (I), wherein R1 is hydrogen, an alkyl or an aryl and R2 is an alkyl or an aryl; R3 is an alkyl; and R4 is an alkyl. Further, the invention relates to novel compositions useful as antioxidants. The novel compounds include: 2,6-di-tert-butyl-4-(N-tert-octyl) nitronyl phenol (DBONP); 2,6-dimethyl-4-(N-tert-octyl) nitronyl phenol (DMONP); N-tert-octyl-C-phenyl nitrone (OPN).

Claims

AMENDED CLAIMS
[received by the International Bureau on 24 April 1995 (24.04.95); original claim 16 cancelled; remaining claims amended (5 pages]
1. A compound having the formula:
Figure imgf000003_0001
wherein Rl is a hydrogen, an aryl, or an alkyl;
R2 is an alkyl or an aryl;
R3 is an alkyl from 1 to 4 carbons in length; and R4 is an alkyl of 1 to 4 carbons in length; for use in the in vivo treatment or prevention of lipid peroxidation.
2. The compound of Claim 1 wherein Rl is hydrogen and R2 is an alkyl.
3. The compound of Claim 1 wherein Rl is an alkyl ,
4. The compound of Claim 1 wherein Rl includes polar substituents selected from the group comprising esters, alcohols, halides, carboxylic acids, aldehydes, carboxamides, aralkyl, amino or nucleic acids.
5. The compound of Claim 1 wherein R2 includes polar substituents selected from the group comprising esters, alcohols, halides, carboxylic acids, aldehydes, carboxamides, aralkyl, amino or nucleic acids. 6. The compound of Claim 1 wherein R3 and R4 are methyl groups.
7. The compound of Claim 1 wherein R3 and R4 are butyl groups.
8. The compound of Claim 1 wherein the compound is provided in a dosage of between about 25 and about 250 mg compound/kg body weight.
9. The compound of Claim 1 wherein the compound is 2 , 6-di-tert-butyl-4- (N-tert-octyl) nitronyl phenol.
10. The compound of Claim 1 wherein the compound is 2, 6-dimethvl-4- (N-tert-octyl) nitronyl phenol.
11. The compound of Claim 1 wherein the compound is 2 , 6-di-tert-butyl-4- (N-tert-butyl) nitronyl phenol.
12. The compound of Claim 1 wherein the compound is 2, 6-dimethyl-4- (N-tert-butyl) nitronyl phenol.
13. The compound of Claim 1 wherein the compound is N-tert-octyl C-phenyl nitrone.
14. The compound of Claim 1 wherein Rl is hydrogen and R2 is an aryl .
15. The compound of Claim 1 wherein the compound is provided in a dosage of between about 25 to about 125 mg compound/kg body weight . 17. A compound of a formula:
Figure imgf000005_0001
18. A compound of a formula:
Figure imgf000005_0002
19. A compound having the formula
Figure imgf000006_0001
wherein R5 is an alkyl; R6 is an alkyl R7 is an alkyl R8 is an alkyl and R9 is an alkyl for use in the in vivo treatment or prevention of lipid peroxidation.
20. The compound of Claim 19 wherein the compound is provided in a dosage of between about 25 mg to about 250 mg compound/kg body weight.
21. The compound of Claim 19 wherein the compound is provided in a dosage of between about 25 mg to about 125 mg compound/kg body weight.
22. A compound according to the formula:
0
Figure imgf000007_0001
wherein R10 is an alkyl of 9 or more carbons.
23. The compound of claim 1 wherein the dosage is from about 25 to about 50 g/kg.
PCT/US1994/012107 1993-10-22 1994-10-20 Novel spin trap nitronyl hindered phenols WO1995011227A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002174628A CA2174628C (en) 1993-10-22 1994-10-20 Novel spin trap nitronyl hindered phenols
DE69420146T DE69420146T2 (en) 1993-10-22 1994-10-20 NEW STERICALLY HIDDEN NITRONYLPHENOLS AS RADICAL CATCHERS ("SPINTRAPS")
EP94931977A EP0724565B1 (en) 1993-10-22 1994-10-20 Novel spin trap nitronyl hindered phenols
AU80869/94A AU696451B2 (en) 1993-10-22 1994-10-20 Novel spin trap nitronyl hindered phenols

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/141,241 1993-10-22
US08/141,241 US5455272A (en) 1993-10-22 1993-10-22 Spin trap nitronyl hindered phenols

Publications (2)

Publication Number Publication Date
WO1995011227A1 WO1995011227A1 (en) 1995-04-27
WO1995011227B1 true WO1995011227B1 (en) 1995-05-18

Family

ID=22494820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012107 WO1995011227A1 (en) 1993-10-22 1994-10-20 Novel spin trap nitronyl hindered phenols

Country Status (6)

Country Link
US (4) US5455272A (en)
EP (1) EP0724565B1 (en)
AU (1) AU696451B2 (en)
DE (1) DE69420146T2 (en)
ES (1) ES2136209T3 (en)
WO (1) WO1995011227A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
DE69625701T2 (en) * 1995-09-11 2003-10-02 Aventis Pharma Inc CYCLIC NITRONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
ATE263559T1 (en) * 1996-04-23 2004-04-15 Centaur Pharmaceuticals Inc PREPARATIONS CONTAINING A NITRONIC COMPOUND FOR USE IN THE TREATMENT OF UVEITIS
EP1021430A1 (en) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (en) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc ALPHA-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
DE69904018D1 (en) * 1998-01-16 2003-01-02 Centaur Pharmaceuticals Inc Thiophennitronderivate
ZA99252B (en) * 1998-01-16 1999-07-14 Centaur Pharmaceuticals Inc Thioether furan nitrone compounds.
ATE271384T1 (en) * 1998-05-19 2004-08-15 Renovis Inc ARYLNITRON THERAPEUTIC AGENTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
CA2333190A1 (en) * 1998-05-19 1999-11-25 Beverly Greenwood-Van Meerveld Furan nitrone therapeutics for the treatment of inflammatory bowel disease
AU4184499A (en) 1998-05-19 1999-12-06 Renovis, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
FR2780404B1 (en) * 1998-06-26 2001-04-13 Adir NOVEL NITRONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2337850A1 (en) * 1998-07-17 2000-01-27 Centaur Pharmaceuticals, Inc. Alpha-(2-hydroxyphenyl) nitrone compounds, pharmaceutical compositions containing the same and their use for treating inflammation
UA66401C2 (en) * 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
IT1312537B1 (en) * 1999-04-16 2002-04-22 Euphar Group Srl DERIVATIVES OF (-) - VERBENONE.
AU2002253857A1 (en) * 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
FR2846968B1 (en) * 2002-11-08 2005-02-04 Salles Jean Pierre NOVEL AMPHIPHILIC DERIVATIVES OF ALPHA-C-PHENYL-N-TERT-BUTYL NITRONE
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
WO2005087214A1 (en) * 2004-03-09 2005-09-22 Renovis, Inc. Methods for treating multiple sclerosis and pharmaceutical compositions therefor
JP4996575B2 (en) * 2007-11-15 2012-08-08 ローム アンド ハース カンパニー Nitron manufacturing
ES2367330T3 (en) * 2007-11-15 2011-11-02 Rohm And Haas Company NITRON PREPARATION.
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
US9452118B2 (en) 2011-11-30 2016-09-27 Dow Global Technologies Llc Nitrone compounds and their use in personal care
CN106061941B (en) 2014-03-07 2018-05-08 陶氏环球技术有限责任公司 Nitrone compound and its use in personal nursing
WO2015175310A1 (en) 2014-05-12 2015-11-19 Dow Global Technologies Llc Nitrone compounds and their use in personal care
EP3161025B1 (en) 2014-06-30 2019-11-13 Dow Global Technologies LLC Polymeric nitrones and their use in personal care
EP3270876B1 (en) * 2015-03-20 2021-12-22 Dow Global Technologies LLC Nitrone inhibition of oxidation of unsaturated fats
CN108024933B (en) * 2015-03-20 2021-04-13 陶氏环球技术有限责任公司 Nitrones to inhibit oxidation of unsaturated fats

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903049A (en) * 1974-01-30 1975-09-02 Goodyear Tire & Rubber Oxidation resistant sulfur curable rubbery polymers
GB2137619A (en) * 1983-03-30 1984-10-10 Gerald Scott Nitrone compounds and stabilised rubber compositions containing them
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
JP2797559B2 (en) * 1989-11-30 1998-09-17 住友化学工業株式会社 Nitrone compound and method for producing the same
ATE209908T1 (en) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADICAL CAPTURER (ßSPIN TRAPSß) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATION OF LIPIDS AND PROTEINS

Similar Documents

Publication Publication Date Title
WO1995011227B1 (en) Novel spin trap nitronyl hindered phenols
CA2153979A1 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
JP2002502874A5 (en)
KR950017957A (en) Preparation and intermediates of 3, 4, 4-trisubstituted-piperidinyl-N-alkylcarboxylates
CA2504730A1 (en) Cephem compounds
KR950016732A (en) How to suppress skin and vaginal atrophy
EP0938317A4 (en) Compositions and methods for reducing respiratory depression
KR950010893A (en) How to suppress endometriosis
KR950016725A (en) How to suppress pulmonary hypertension diseases
CA2192555A1 (en) 2-acylaminopropanol compound and medicinal composition
KR950010892A (en) How to suppress uterine fibrosis
KR950016723A (en) How to suppress autoimmune diseases
CA2015475A1 (en) Treating agent for osteoarthritis
CA2190993A1 (en) Protective agent for organ or tissue
RU2003134629A (en) CEPHEMA COMPOUNDS
CA2433039A1 (en) Agent for therapeutic and prophylactic treatment of neuropathic pain
CA2241092A1 (en) 1-methylcarbapenem derivatives
KR950016735A (en) How to suppress Turner syndrome
RU94044357A (en) Use of 2-phenyl-3-aroylbenzothiophenes for inhibiting weight increase, inducing weight decrease or inhibiting appetite
CA2317673A1 (en) Novel allylthiopyridazine derivatives and process for preparing the same
CA2441309A1 (en) Biguanide derivatives
GB9125970D0 (en) New compounds
CA2118425A1 (en) Benzothiazolesulfonamide derivative, Method for Preparing the Same, and Use Thereof
CA2089207A1 (en) Amphoteric Tricyclic Compound
CA2290724A1 (en) Glycopeptide hexapeptides